Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Personalized treatment is crucial for effectively managing benign prostatic hyperplasia (BPH).

5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.

5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.

5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.

5α-reductase inhibitors can interfere with doping tests by masking banned substances.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

Oral finasteride and dutasteride may negatively affect erectile function in rats.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

Finasteride can cause melasma, especially in people with darker skin.

Finasteride can cause melasma, especially in people with darker skin.

Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.

5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.

5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.

5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.

Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.

Frontal fibrosing alopecia in men is often misdiagnosed and needs better diagnostic criteria and treatments.

Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.